Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Biodesix, Inc.NASDAQ: BDSX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $25.56M rose 42.3% year over year, ahead of the +29.1% change in trailing-twelve-month revenue. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at +32.3% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 5 analysts of $103.29M (+16.7%) for the fiscal year ending Dec 2026, a slowdown from the +24.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.56M-11.1% QoQ
Last fiscal yearDec 2025
$88.5M+24.1% YoY
LTMMar 2026
$96.1M+29.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.3%+30.0%-12.3 pp
1 year+24.1%+16.7%-7.4 pp
3-year CAGR+32.3%+18.6%-13.7 pp
5-year CAGR+17.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
88.5M USD
Year-over-year change
+24.1%
4-year CAGR
+12.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 revenue of $96.1M is the highest of the 5 companies compared; the peer median is $0.
  • Its year-over-year change of +29.1% is the 2nd highest of 3, against a peer median of +188.4%.
  • Over three fiscal years its annual growth of +32.3% compares with a peer median of -48.9%.
BDSX Competitors Peer median
Revenue for BDSX and competitors
Company Period LTM YoY 3-year CAGR
BDSXBiodesix, Inc.LTM Mar 2026$96.1M +29.1%+32.3%
XLOXilio Therapeutics, Inc.LTM Mar 2026$53.48M +476.7%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$0 ——
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 ——
INMBINmune Bio, Inc.LTM Mar 2026$0 -100.0%-48.9%
Peer median (excluding BDSX) $0+188.4%-48.9%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue54.51M38.21M49.09M71.32M88.5M
Cost of Revenue30.52M14.15M13.01M15.57M16.72M
Gross Profit23.99M24.06M36.08M55.75M71.78M
Gross Margin44.0%63.0%73.5%78.2%81.1%
Research & Development12.79M13.1M9.99M9.56M12M
Selling, General & Admin50.52M61.46M67.39M80.45M87.55M
Operating Expenses64.93M74.65M77.42M90.25M99.55M
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
EBITDA(35.47M)(51.53M)(37.1M)(29.22M)(21.95M)
EBITDA Margin-65.1%-134.9%-75.6%-41.0%-24.8%
Operating Income(40.94M)(50.59M)(41.34M)(34.5M)(27.77M)
Operating Margin-75.1%-132.4%-84.2%-48.4%-31.4%
Interest Income00000
Interest Expense4.51M8.07M9.54M8.26M7.72M
Other Income / Expenses(2.22M)(14.86M)(10.8M)(8.43M)(7.5M)
Income Before Tax(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Pre-Tax Margin-79.2%-171.3%-106.2%-60.2%-39.8%
Income Tax Expense00000
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Net Margin-79.2%-171.3%-106.2%-60.2%-39.8%
EPS (Basic)(31.60)(31.00)(12.80)(6.60)(4.67)
EPS (Diluted)(31.60)(31.00)(12.80)(6.60)(4.67)
Weighted Avg Shares1.37M2.11M4.11M6.48M7.55M
Weighted Avg Shares (Diluted)1.37M2.11M4.11M6.48M7.55M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.